Edema factor (EF), a key virulence factor in anthrax pathogenesis, has calmodulin (CaM)-activated adenylyl cyclase activity. We have found that adefovir dipivoxil, a drug approved to treat chronic infection of hepatitis B virus, effectively inhibits EF-induced cAMP accumulation and changes in cytokine production in mouse primary macrophages. Adefovir diphosphate (PMEApp), the active cellular metabolite of adefovir dipivoxil, inhibits the adenylyl cyclase activity of EF in vitro with high affinity (Ki ‫؍‬ 27 nM). A crystal structure of EF-CaM-PMEApp reveals that the catalytic site of EF forms better van der Waals contacts and more hydrogen bonds with PMEApp than with its endogenous substrate, ATP, providing an explanation for the Ϸ10,000-fold higher affinity EF-CaM has for PMEApp versus ATP. Adefovir dipivoxil is a clinically approved drug that can block the action of an anthrax toxin. It can be used to address the role of EF in anthrax pathogenesis.
T he spore-forming Bacillus anthracis secretes three major toxins: edema factor (EF), protective antigen (PA), and lethal factor (LF) (1, 2) . As an adenylyl cyclase, EF raises the concentration of a second messenger, cyclic AMP (cAMP), inside host cells to supraphysiological levels (3, 4) . An inactivating mutation in EF results in reduced survival of germinated anthrax spores in macrophages, indicating an active role for EF at early stages of anthrax infection (5) . EF also modulates the profile of cytokines such as tumor necrosis factor ␣ (TNF-␣) and interleukin 6 (IL-6) produced by human monocytes, which could impair cellular antimicrobial responses (6) . Consequently, a strain of anthrax with a defective EF gene has 100-fold reduced lethality in mice (7) .
EF enters host cells via a complex with PA, which is a pH-dependent protein transporter (8) . LF, a zinc metalloprotease that inactivates mitogen-activated protein kinase kinase, also enters into host cells by its association with PA (9, 10) . LF works coordinately with EF to facilitate bacterial survival in macrophages and to impair host innate immunity (5-7, 11, 12) . The combination of toxemia caused by anthrax toxins and bacteremia due to the rapid growth of anthrax bacteria in vital organs can result in sepsis, pulmonary edema, and͞or meningitis within days, making inhalational anthrax a deadly disease.
Natural isolates of B. anthracis are sensitive to a broad spectrum of antibiotics; thus antibiotics have been the primary recourse for therapy (13) . However, antibiotics are ineffective against either toxemia or antibiotic-resistant strains of anthrax. The antibiotic treatment used for victims of the 2001 bioterrorism-related anthrax attack in the United States resulted in a survival rate of slightly better than 50% for cases of inhalational anthrax. Some survivors have experienced illness with symptoms such as fatigue, shortness of breath, chest pain, and memory loss. However the limited patient sample size does not allow an accurate assessment as to whether such symptoms are anthrax sequelae or not. This situation highlights an urgent need for a more effective treatment to improve the survival rate and quality of life of patients suffering from inhalational anthrax due to future acts of bioterrorism (14) .
Clinically approved drugs represent the chemical space that has the favorable pharmacological properties necessary to provide patients with therapeutic benefits (15 In Vitro Adenylyl Cyclase Assay. The plasmid for the expression of the catalytic domains of EF and adenylyl cyclase toxin (EF3 and CyaA-N) as well as EF3 mutants were constructed and the recombinant proteins were purified from Escherichia coli as described (16) . Sf9 insect cells were infected with recombinant baculoviruses for the expression of type I, type II, and type V adenylyl cyclase, and membranes of Sf9 cells containing the overexpressed cyclases were prepared as described (17) . Recombinant ␣-subunit of GS protein (Gs␣) was purified from E. coli by using Ni-NTA and Q-Sepharose columns (18 cyclase activity of EF-3 and CyaA-N was measured at 30°C for 10 min in the presence of 20 mM Hepes (pH 7.2), 10 mM (16) . ATP and cAMP were separated by a two-column method (Dowex and alumina) and adenylyl cyclase activities were calculated. The adenylyl cyclase activity of 20 g of Sf9 cell membrane, stimulated by 500 nM Gs␣ and 100 M forskolin, was measured at 30°C for 20 min in the presence of 50 M AlCl 3 , 10 mM MgCl 2 , and 10 mM NaF as described (17) .
Tissue Culture. Cells were maintained in DMEM͞F12 supplemented with 1% L-glutamine and 1% penicillin͞1% streptomycin. For Chinese hamster ovary (CHO) cells, 10% calf serum was added; for adrenocortical Y1 cells, 2.5% FBS and 12.5% horse serum were added. Mouse bone marrow (BM) cells were collected by flushing femurs and tibias of C57BL͞6 mice with Hanks' balanced salt solution. BM-derived macrophages (BMM⌽) were propagated from BM progenitors in RPMI medium 1640 supplemented with 10% FCS (RPMI-10) and 30% L929-conditioned medium. After 5 days, nonadherent cells were removed and adherent ones were recovered by incubation with trypsin͞EDTA at 37°C for 5 min and plated for experiments.
cAMP Accumulation in CHO and BMM⌽ Cells and Morphology Change in Adrenocortical Y1 Cells. Recombinant EF and PA were expressed and purified as described (19) . To measure cAMP accumulation inside cells, the cells were seeded in a 24-well plate either at 7.5 ϫ 10 PMEA to PMEApp inside cells, bis-POM-PMEA was added 5-8 h before treatment of the cells with ET, and fresh drug was added again 1 h before addition of ET. ET or forskolin was added and cells were incubated for an additional 1-2 h. The levels of cAMP were determined by enzyme immunoassay (Biotrak EIA, Amersham Pharmacia). Morphological changes in adrenocortical Y1 cells were examined as described (19) .
Cytokine Production. To study the effect of ET on TNF-␣ production, BMM⌽ (5 ϫ 10 5 cells per well) were treated with various concentrations of ET and cultured in the presence (for TNF-␣) or absence (for IL-6) of E. coli O111:B4 lipopolysaccharide (LPS; 5 g͞ml, Sigma) in a final volume of 500 l of RPMI-10. To examine the effect of bis-POM-PMEA on cytokine production, BMM⌽ were pretreated with various concentrations for 5 h. Cells were then stimulated with ET plus LPS (for TNF-␣) or ET alone, and received a second drug treatment. Twenty hours later, the culture supernatants were harvested, and the levels of TNF-␣ and IL-6 were quantified by sandwich ELISA (Pharmingen).
Structure Determination. Crystals of the EF3-CH6-CaM complex were grown to a size greater than 0.4 mm ϫ 0.4 mm ϫ 0.4 mm. The isolated single crystals were soaked with 2 mM PMEApp overnight during cryoprotection and flash-frozen in liquid nitrogen as described (20) . Data were collected at 100 K at the Advanced Photon Source Structural Biology Center Beamline 19-ID, Argonne National Laboratory, and processed by using HKL2000 (21) . The initial solutions were obtained by difference Fourier method using CNS and a model of the EF3-CaM complex (22) . The final model was refined by CNS, O, and TURBO-FRODO (Table 1 , which is published as supporting information on the 
PNAS web site
). The coordinates for EF3-CaM-PMEApp are available from the Protein Data Bank (ID code 1PK0).
Results

Characterization of PMEApp as a Potent and Specific Inhibitor of EF.
Acyclic nucleoside phosphonates represent a class of nucleotide analogues approved for a variety of viral infections, which include cidofovir [(cytomegalovirus (CMV)], tenofovir [human immunodeficiency virus (HIV)], and adefovir [hepatitis B virus (HBV)] (23). bis-POM-PMEA (Hepsera, Gilead Sciences) (Fig.  1A) is an orally bioavailable prodrug of adefovir (PMEA), an analogue of adenosine monophosphate (AMP) approved for the treatment of chronic HBV infection (23, 24) . Inside the cells, PMEA is converted by cellular kinases to the diphosphate derivative PMEApp, a noncyclizable ATP analogue (Fig. 1B) . PMEApp is a competitive inhibitor and chain terminator of HBV DNA replication by HBV DNA polymerase (K i ϭ 100 nM) (25) . In an in vitro adenylyl cyclase assay, we found that PMEApp has almost 10,000-fold higher affinity for the EF-CaM complex (K i ϭ 27 nM, Fig. 1B ) than the endogenous substrate, ATP (K m ϭ 168-194 M; Fig. 5 ) and 4-fold higher affinity than the affinity for its original therapeutic target, HBV DNA polymerase (Figs. 1B and 5) (25) . Kinetic analysis revealed that PMEApp inhibits the catalytic activity of EF by competing with the binding of ATP (Fig. 1C) . Quantitative structure-activity relationship (QSAR) analysis (Figs. 1B and 5) revealed that the addition of a methyl group at the 2Ј position of PMEApp to create 9-[2-(phosphonomethoxy)propyl)]adenine diphosphate (PMPApp) resulted in 7-fold lower affinity, whereas the addition of an amino group at the C2 position of the adenine base to create 9-[2-(phosphonomethoxy)ethyl]-2,6-diaminopurine diphosphate (PMEDAPpp) generated Ϸ2-fold lower affinity. Furthermore, when these two substitutions were combined in 9-[2-(phosphonomethoxy)propyl]-2,6-diaminopurine diphosphate (PMPDAPpp), the effects were additive and a 15-fold reduction in affinity was observed.
Fig. 2. Effects of bis-POM-PMEA on ET-induced cAMP accumulation in CHO cells (A) and mouse BMM⌽ (B)
. Cells were pretreated with bis-POM-PMEA for 5 h, then fresh bis-POM-PMEA was reapplied together with ET (5 ng͞ml EF and 25 ng͞ml PA for CHO and 30 ng͞ml EF and 300 ng͞ml PA for BMM⌽). For comparison, forskolin (Fsk; 100 M for CHO cells and 10 M for BMM⌽) was used to elevate intracellular cAMP levels. Mean Ϯ SE is representative of at least two experiments. We also tested the effect of PMEApp and its analogues on the catalytic activity of CyaA, an adenylyl cyclase toxin with 35% amino acid sequence identify to EF. CyaA is secreted by Bordetella pertussis, the causative agent of whooping cough, and it is vital for bacterial colonization in vivo (26) . We found that PMEApp also competitively inhibits the activity of CyaA with a K i of 25 nM (Figs. 1B and 6 ). The QSAR profile of PMEApp analogues against CyaA was parallel to the profile for EF (Fig.  1B) . Because it was the most potent inhibitor of EF, we focused our subsequent efforts on PMEApp.
We examined the ability of PMEApp to inhibit host mammalian adenylyl cyclases (mACs). At least nine isoforms of membrane-bound mAC as well as one testis-specific soluble mAC have been characterized (27, 28) . We examined the effect of PMEApp on the Gs␣-and forskolin-stimulated activity of mAC types I, II, and V, representing the three major families of mAC. We found that PMEApp had 10-to 20-fold lower affinity for mouse type V and bovine type I mAC than for EF (Fig. 1D) , similar to the reported affinity of PMEApp for rat brain adenylyl cyclase (29) . Even at a concentration of 10 M, PMEApp exhibited little inhibition of type II mAC (Fig. 1D) . Such selectivity for EF and CyaA over mAC suggests that PMEApp may be used at concentrations that neutralize the bacterial toxins effectively without deleterious side effects through interference with host mACs.
Effectiveness of the Antiviral Drug Bis-POM-PMEA in Blocking EFInduced cAMP Accumulation and Altering Cytokine Production in
Primary Macrophages. Encouraged by the selectivity demonstrated in enzymatic assays, we tested whether bis-POM-PMEA, the prodrug of PMEApp (Fig. 1 A) , could block the biological effects of edema toxin (ET, the combination of EF and PA) on cells. We found that bis-POM-PMEA could effectively inhibit ET-induced cAMP accumulation in CHO cells with an IC 50 value around 0.1 M (Fig. 2A) . Bis-POM-PME was 20-fold less effective in inhibiting the cAMP accumulation stimulated by forskolin, a diterpene that stimulates most mACs (Fig. 2 A) (27) , consistent with the selectivity for EF over mACs observed in the enzymatic assays. We also found that bis-POM-PMEA could prevent ET-induced morphological changes in Y1 cells, a mouse adrenocortical cell line previously used to monitor ET effects (Fig. 7 , which is published as supporting information on the PNAS web site) (19) .
Macrophages play key roles in anthrax pathogenesis (5, 6, 30) . In the early stages of infection, spores germinate in and are disseminated by macrophages. However, in the later stage of infection, anthrax toxins modify the functions of or kill macrophages. We thus examined the effect of bis-POM-PMEA on BMM⌽. We found that ET could raise intracellular cAMP levels in BMM⌽ in a dose-dependent manner that could be blocked by bis-POM-PMEA. Bis-POM-PMEA was significantly less effective in blocking cAMP accumulation induced by forskolin (Fig.  2B) . ET has been shown to down-regulate the production of TNF-␣ in human mononuclear phagocytes after stimulation with LPS (6) . Similarly, we found that ET significantly reduced LPS-induced TNF-␣ production by BMM⌽ (Fig. 3A) . Preincubation of BMM⌽ with bis-POM-PMEA effectively reversed the EF-mediated down-regulation of TNF-␣ production (Fig. 3B) . ET has also been shown to induce IL-6 production by human monocytes; we found a similar effect in BMM⌽ (Fig. 3C) (6) . The addition of bis-POM-PMEA significantly reduced ET's effect on IL-6 production in BMM⌽ (Fig. 3D) . Taken together, our data indicate that bis-POM-PMEA can effectively inhibit ET-induced cAMP accumulation and the alteration of cytokine production in macrophages.
Molecular Basis for the High Affinity Between EF-CaM and PMEApp.
PMEApp displays an affinity for the EF catalytic site that is four orders of magnitude higher than the affinity of ATP for EF. To determine the molecular basis for this higher affinity, we determined the molecular structure of EF-CaM in complex with PMEApp at a resolution of 3.3 Å ( Table 1 ). The electron density of PMEApp is clearly visible at the catalytic site (Fig.  4A ). PMEApp forms a network of salt bridges and hydrogen bonds with the amino acids at the catalytic site of EF (Fig. 4B) . The adenine base and triphosphate moieties of PMEApp make contacts with EF similar to those of 3Ј-deoxy-ATP (3ЈdATP, a noncyclizable ATP analogue) (Fig. 4C) (4) . Consistent with our structures, in which Lys-372 of EF forms a salt bridge with the ␥-phosphate of both substrates, a mutation replacing Lys-372 with Ala (K372A) resulted in a 40-fold increase in the K i for PMEApp as well as a 10-fold increase in the K m for ATP (Figs. 4D and 8) . Although PMEApp and 3ЈdATP use similar modes of binding to EF, PMEApp has significantly more van der Waals interactions with the ventral cleft of the catalytic site of EF than does 3ЈdATP (Fig. 4C) . Furthermore, PMEApp forms additional hydrogen bonds with EF, including the interaction of adenine N3 and N9 with Asn-583 and that of the methoxy group with His-577 (Fig. 4C) . The importance of these hydrogen bonds in the PMEApp-EF-CaM complex is supported by the finding that the replacement of Asn-583 with Ala (N593A) and His-577 with Asn (H577N) significantly increased the K i values for PMEApp (30-and 80-fold reduction, respectively) but had only a minor effect on the K m for ATP (Figs. 4D and 8 ). In addition, PMEApp has more negative charges in the nonbridging oxygens of the ␣-phosphate, which mimic the pentavalent transition state for the cyclization reaction of EF (31) . Because enzymes have evolved to have substantially better bonding in the transition state than in the ground state, mimicking the transition state could significantly contribute to the affinity of PMEApp for EF (32) . Taken together, better van der Waals contacts, additional hydrogen bonds, and transition state mimicry likely explain why PMEApp has 10,000-fold higher affinity for EF than does ATP.
Discussion
The fatalities and long term disabilities resulting from the bioterrorism-related anthrax in 2001 have highlighted the need to effectively prevent and treat the symptoms and sequelae of inhalational anthrax. The pathogenesis of anthrax is mediated by the combination of toxemia and bacteremia. Therefore, effective treatment must block both the actions of anthrax toxins and the growth of anthrax bacteria. Several potential antitoxins have been developed recently (19, (33) (34) (35) (36) . However, extensive modifications and testing will be required to realize their therapeutic potential. Bis-POM-PMEA is the first clinically approved drug that can block the action of an anthrax toxin in vitro. Our studies suggest that bis-POM-PMEA may be a promising adjunctive therapy against anthrax and other human diseases caused by pathogenic bacteria that secrete adenylyl cyclase toxins, such as Bordetella pertussis (whooping cough), Pseudomonas aeruginosa (nosocomial infections), and Yersinia pestis (plague) (26, 37, 38) .
The active metabolite of bis-POM-PMEA, PMEApp, is a slightly more potent inhibitor of the adenylyl cyclase activity of EF (K i ϭ 27 nM) than of its approved therapeutic target, HBV DNA polymerase (K i ϭ 100 nM) (25) . Correspondingly, the effective concentrations of bis-POM-PMEA required for inhibition of the cellular effects induced by ET (IC 50 ϭ 0.1-0.5 M) are comparable to those reported for inhibition of HBV DNA replication by bis-POM-PMEA in hepatoblastoma cells in vitro (IC 50 ϭ 0.7-1.2 M) (39). Because bis-POM-PMEA possesses favorable pharmacological properties that permit once-daily oral administration of a relatively low dose (10 mg) for the treatment of chronic hepatitis B, further studies are warranted to determine whether bis-POM-PMEA can exert antitoxin activity in vivo. In addition, the molecular structures of EF-CaM in complex with PMEApp as well as the molecular structure of the catalytic domain of mACs are available to provide a structural blueprint to further improve the affinity and selectivity of PMEA for EF for the next generation of drugs (40) . Further studies are required to determine whether bis-POM-PMEA (or a related member of this class of acyclic nucleotide analogues) can be used experimentally to assess the role of adenylyl cyclase toxins in bacterial pathogenesis as well as clinically to provide protection against several deadly human diseases.
